glycoprotein	verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
glycoprotein	verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
glycoprotein	Verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	Verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	Verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
glycoprotein	Verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
procaine	basis	23	23	false	none	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	0	8701	1046801
procaine	basis	23	23	false	none	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	0	8701	1046801
procaine	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
procaine	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
procaine	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
procaine	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
basis	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
basis	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
basis	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
basis	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
verapamil	Norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	none
verapamil	Norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	none
verapamil	Norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	none
verapamil	Norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	none
verapamil	Norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	none
verapamil	Norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	none
verapamil	Norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	Norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	Norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	none
verapamil	Norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	none
verapamil	Norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	none
verapamil	Norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	none
verapamil	relaxant	29	30	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	relaxant	29	30	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	relaxant	31	30	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	none	11170	none
verapamil	relaxant	31	30	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	none	11170	none
verapamil	relaxant	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	relaxant	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	verapamil hydrochloride	34	36	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	34	36	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	36	36	false	none	The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	36	36	false	none	The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	42	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	42	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	41	42	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	41	42	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	47	48	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	47	48	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	47	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	47	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	47	45	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	47	45	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	45	47	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	45	47	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	45	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	45	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	48	48	false	none	Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	48	48	false	none	Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	48	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	48	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	55	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	55	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	55	57	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	55	57	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	54	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	54	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	59	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	59	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	58	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	58	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	57	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	57	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	0	11170	D014700
verapamil	verapamil hydrochloride	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	0	11170	D014700
verapamil	Verapamil	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist).  		11170	11170
verapamil	Verapamil	1	2	true	positive	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist).  Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  		11170	11170
verapamil	Verapamil	1	3	true	positive	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist).  Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  		11170	11170
verapamil	Verapamil	2	1	true	positive	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist).  Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  		11170	11170
verapamil	Verapamil	2	2	false	none	Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  		11170	11170
verapamil	Verapamil	2	3	false	none	Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  		11170	11170
verapamil	Verapamil	2	4	false	none	Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus.  		11170	11170
verapamil	Verapamil	3	1	true	positive	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist).  Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  		11170	11170
verapamil	Verapamil	3	2	false	none	Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  		11170	11170
verapamil	Verapamil	3	3	false	none	Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  		11170	11170
verapamil	Verapamil	3	4	false	none	Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus.  		11170	11170
verapamil	Verapamil	4	2	false	none	Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.  Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus.  		11170	11170
verapamil	Verapamil	4	3	false	none	Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced.  In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus.  		11170	11170
verapamil	Verapamil	4	4	false	none	In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus.  		11170	11170
verapamil	Verapamil	8	8	false	none	12.2 Pharmacodynamics    Essential Hypertension    Verapamil produces its antihypertensive effect by a combination of vascular and cardiac effects.  		11170	11170
verapamil	Verapamil	12	12	false	none	During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.  		11170	11170
verapamil	Verapamil	12	13	false	none	During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.  Verapamil does not alter total serum calcium levels.  		11170	11170
verapamil	Verapamil	12	14	false	none	During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.  Verapamil does not alter total serum calcium levels.  However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  		11170	11170
verapamil	Verapamil	13	12	false	none	During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.  Verapamil does not alter total serum calcium levels.  		11170	11170
verapamil	Verapamil	13	13	false	none	Verapamil does not alter total serum calcium levels.  		11170	11170
verapamil	Verapamil	13	14	false	none	Verapamil does not alter total serum calcium levels.  However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  		11170	11170
verapamil	Verapamil	13	15	false	none	Verapamil does not alter total serum calcium levels.  However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.  		11170	11170
verapamil	Verapamil	14	12	false	none	During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.  Verapamil does not alter total serum calcium levels.  However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  		11170	11170
verapamil	Verapamil	14	13	false	none	Verapamil does not alter total serum calcium levels.  However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  		11170	11170
verapamil	Verapamil	14	14	false	none	However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  		11170	11170
verapamil	Verapamil	14	15	false	none	However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.  		11170	11170
verapamil	Verapamil	15	13	false	none	Verapamil does not alter total serum calcium levels.  However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.  		11170	11170
verapamil	Verapamil	15	14	false	none	However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.  Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.  		11170	11170
verapamil	Verapamil	15	15	true	positive	Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.  		11170	11170
verapamil	Verapamil	15	17	false	none	Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.  Electrophysiologic Effects    Electrical activity through the AV node depends, to a significant degree, upon the transmembrane influx of extracellular calcium through the L-type (slow) channel.  By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.  		11170	11170
verapamil	Verapamil	17	15	false	none	Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.  Electrophysiologic Effects    Electrical activity through the AV node depends, to a significant degree, upon the transmembrane influx of extracellular calcium through the L-type (slow) channel.  By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.  		11170	11170
verapamil	Verapamil	17	17	false	none	By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.  		11170	11170
verapamil	Verapamil	17	18	false	none	By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.  Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block.  		11170	11170
verapamil	Verapamil	18	17	false	none	By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.  Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block.  		11170	11170
verapamil	Verapamil	18	18	false	none	Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block.  		11170	11170
verapamil	Verapamil	18	20	true	negative	Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block.  Atrioventricular block can occur in patients without preexisting conduction defects [see Warnings and Precautions (5.5)].  Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers.  		11170	11170
verapamil	Verapamil	21	21	false	none	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  		11170	11170
verapamil	Verapamil	21	20	false	none	Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers.  Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  		11170	11170
verapamil	Verapamil	21	23	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		11170	11170
verapamil	Verapamil	21	22	false	none	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  		11170	11170
verapamil	Verapamil	20	18	true	negative	Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block.  Atrioventricular block can occur in patients without preexisting conduction defects [see Warnings and Precautions (5.5)].  Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers.  		11170	11170
verapamil	Verapamil	20	21	false	none	Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers.  Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  		11170	11170
verapamil	Verapamil	20	20	false	none	Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers.  		11170	11170
verapamil	Verapamil	20	22	false	none	Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers.  Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  		11170	11170
verapamil	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		11170	11170
verapamil	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		11170	11170
verapamil	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		11170	11170
verapamil	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		11170	11170
verapamil	Verapamil	22	21	false	none	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  		11170	11170
verapamil	Verapamil	22	20	false	none	Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers.  Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  		11170	11170
verapamil	Verapamil	22	23	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		11170	11170
verapamil	Verapamil	22	22	false	none	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  		11170	11170
verapamil	Verapamil	25	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		11170	11170
verapamil	Verapamil	25	25	false	none	Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		11170	11170
verapamil	Verapamil	25	27	false	none	Hemodynamics    Verapamil reduces afterload and myocardial contractility.  In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged.  During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function.  		11170	11170
verapamil	Verapamil	25	26	false	none	Hemodynamics    Verapamil reduces afterload and myocardial contractility.  In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged.  		11170	11170
verapamil	Verapamil	27	25	false	none	Hemodynamics    Verapamil reduces afterload and myocardial contractility.  In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged.  During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function.  		11170	11170
verapamil	Verapamil	27	27	false	none	During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function.  		11170	11170
verapamil	Verapamil	27	26	false	none	In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged.  During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function.  		11170	11170
verapamil	Verapamil	27	29	false	none	During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function.  In patients with severe left ventricular dysfunction (e.g.,  pulmonary wedge pressure above 20 mm Hg or ejection fraction less than 30%), or in patients taking beta-adrenergic blocking agents or other cardiodepressant drugs, deterioration of ventricular function may occur [see Drug Interactions (7.3)].  Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  		11170	11170
verapamil	Verapamil	26	25	false	none	Hemodynamics    Verapamil reduces afterload and myocardial contractility.  In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged.  		11170	11170
verapamil	Verapamil	26	27	false	none	In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged.  During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function.  		11170	11170
verapamil	Verapamil	26	26	false	none	In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged.  		11170	11170
verapamil	Verapamil	29	27	false	none	During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function.  In patients with severe left ventricular dysfunction (e.g.,  pulmonary wedge pressure above 20 mm Hg or ejection fraction less than 30%), or in patients taking beta-adrenergic blocking agents or other cardiodepressant drugs, deterioration of ventricular function may occur [see Drug Interactions (7.3)].  Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  		11170	11170
verapamil	Verapamil	29	29	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  		11170	11170
verapamil	Verapamil	29	31	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	11170
verapamil	Verapamil	29	30	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	11170
verapamil	Verapamil	31	29	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	11170
verapamil	Verapamil	31	31	false	none	12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	11170
verapamil	Verapamil	31	30	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	11170
verapamil	Verapamil	31	33	false	none	12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  The systemic concentrations of R and S enantiomers, as well as overall bioavailability, are dependent upon the route of administration and the rate and extent of release from the dosage forms.  Upon oral administration, there is rapid stereoselective biotransformation during the first pass of verapamil through the portal circulation.  		11170	11170
verapamil	Verapamil	30	29	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	11170
verapamil	Verapamil	30	31	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	11170
verapamil	Verapamil	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	11170
verapamil	Verapamil	34	34	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  		11170	11170
verapamil	Verapamil	34	33	true	positive	Upon oral administration, there is rapid stereoselective biotransformation during the first pass of verapamil through the portal circulation.  Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  		11170	11170
verapamil	Verapamil	34	36	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		11170	11170
verapamil	Verapamil	33	31	false	none	12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  The systemic concentrations of R and S enantiomers, as well as overall bioavailability, are dependent upon the route of administration and the rate and extent of release from the dosage forms.  Upon oral administration, there is rapid stereoselective biotransformation during the first pass of verapamil through the portal circulation.  		11170	11170
verapamil	Verapamil	33	34	true	positive	Upon oral administration, there is rapid stereoselective biotransformation during the first pass of verapamil through the portal circulation.  Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  		11170	11170
verapamil	Verapamil	33	33	false	none	Upon oral administration, there is rapid stereoselective biotransformation during the first pass of verapamil through the portal circulation.  		11170	11170
verapamil	Verapamil	36	34	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		11170	11170
verapamil	Verapamil	36	36	false	none	The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		11170	11170
verapamil	Verapamil	42	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		11170	11170
verapamil	Verapamil	42	41	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		11170	11170
verapamil	Verapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	11170
verapamil	Verapamil	41	42	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		11170	11170
verapamil	Verapamil	41	41	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  		11170	11170
verapamil	Verapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	11170
verapamil	Verapamil	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	11170
verapamil	Verapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	11170
verapamil	Verapamil	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	11170
verapamil	Verapamil	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	11170
verapamil	Verapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	11170
verapamil	Verapamil	47	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	11170
verapamil	Verapamil	47	45	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	11170
verapamil	Verapamil	47	48	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	11170
verapamil	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	11170
verapamil	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	11170
verapamil	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	11170
verapamil	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	11170
verapamil	Verapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	11170
verapamil	Verapamil	45	47	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	11170
verapamil	Verapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	11170
verapamil	Verapamil	45	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	11170
verapamil	Verapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	11170
verapamil	Verapamil	48	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	11170
verapamil	Verapamil	48	48	false	none	Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	11170
verapamil	Verapamil	55	55	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		11170	11170
verapamil	Verapamil	55	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		11170	11170
verapamil	Verapamil	55	57	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		11170	11170
verapamil	Verapamil	54	55	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		11170	11170
verapamil	Verapamil	54	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  		11170	11170
verapamil	Verapamil	59	59	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		11170	11170
verapamil	Verapamil	59	58	false	none	However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		11170	11170
verapamil	Verapamil	59	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		11170	11170
verapamil	Verapamil	59	60	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  		11170	11170
verapamil	Verapamil	58	59	false	none	However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		11170	11170
verapamil	Verapamil	58	58	false	none	However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		11170	11170
verapamil	Verapamil	58	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		11170	11170
verapamil	Verapamil	58	60	false	none	However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  		11170	11170
verapamil	Verapamil	57	55	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		11170	11170
verapamil	Verapamil	57	59	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		11170	11170
verapamil	Verapamil	57	58	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		11170	11170
verapamil	Verapamil	57	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		11170	11170
verapamil	Verapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	11170
verapamil	Verapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	11170
verapamil	Verapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	11170
verapamil	Verapamil	60	59	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  		11170	11170
verapamil	Verapamil	60	58	false	none	However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  		11170	11170
verapamil	Verapamil	60	60	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  		11170	11170
verapamil	Verapamil	68	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  		11170	11170
verapamil	Verapamil	68	69	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		11170	11170
verapamil	Verapamil	68	70	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		11170	11170
verapamil	Verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		11170	11170
verapamil	Verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		11170	11170
verapamil	Verapamil	69	70	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		11170	11170
verapamil	Verapamil	69	71	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		11170	11170
verapamil	Verapamil	70	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		11170	11170
verapamil	Verapamil	70	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		11170	11170
verapamil	Verapamil	70	70	false	none	In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		11170	11170
verapamil	Verapamil	70	71	false	none	In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		11170	11170
verapamil	Verapamil	70	72	true	positive	In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  		11170	11170
verapamil	Verapamil	71	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		11170	11170
verapamil	Verapamil	71	70	false	none	In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		11170	11170
verapamil	Verapamil	71	71	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		11170	11170
verapamil	Verapamil	71	72	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  		11170	11170
verapamil	Verapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	11170
verapamil	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	11170
verapamil	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	11170
verapamil	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	11170
verapamil	Verapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	11170
verapamil	Verapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	11170
verapamil	Verapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	11170
verapamil	Verapamil	76	76	true	positive	Older subjects had mean AUCs that were approximately 1.7 to 2 times higher than those of younger subjects as well as a longer average verapamil t (approximately 20 hr vs. 13 hr).  		11170	11170
verapamil	Verapamil	76	74	false	none	Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  Older subjects had mean AUCs that were approximately 1.7 to 2 times higher than those of younger subjects as well as a longer average verapamil t (approximately 20 hr vs. 13 hr).  		11170	11170
verapamil	Verapamil	76	75	true	positive	Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  Older subjects had mean AUCs that were approximately 1.7 to 2 times higher than those of younger subjects as well as a longer average verapamil t (approximately 20 hr vs. 13 hr).  		11170	11170
verapamil	Verapamil	72	70	true	positive	In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  		11170	11170
verapamil	Verapamil	72	71	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  		11170	11170
verapamil	Verapamil	72	72	true	positive	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  		11170	11170
verapamil	Verapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	11170
verapamil	Verapamil	72	74	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	11170
verapamil	Verapamil	73	71	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	11170
verapamil	Verapamil	73	72	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	11170
verapamil	Verapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	11170
verapamil	Verapamil	73	74	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	11170
verapamil	Verapamil	73	75	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	11170
verapamil	Verapamil	74	76	false	none	Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  Older subjects had mean AUCs that were approximately 1.7 to 2 times higher than those of younger subjects as well as a longer average verapamil t (approximately 20 hr vs. 13 hr).  		11170	11170
verapamil	Verapamil	74	72	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	11170
verapamil	Verapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	11170
verapamil	Verapamil	74	74	false	none	Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	11170
verapamil	Verapamil	74	75	false	none	Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	11170
verapamil	Verapamil	75	76	true	positive	Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  Older subjects had mean AUCs that were approximately 1.7 to 2 times higher than those of younger subjects as well as a longer average verapamil t (approximately 20 hr vs. 13 hr).  		11170	11170
verapamil	Verapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	11170
verapamil	Verapamil	75	74	false	none	Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	11170
verapamil	Verapamil	75	75	false	none	Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	11170
verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Norverapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	0	none	D014700
Norverapamil	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	11170	none	11170
Norverapamil	Verapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	11170	none	11170
Norverapamil	Verapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	46	false	none	Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	46	false	none	Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	11170	none	11170
Norverapamil	Verapamil	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	11170	none	11170
Norverapamil	Verapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	11170	none	11170
Norverapamil	Verapamil	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	11170	none	11170
Norverapamil	Verapamil	73	71	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	71	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	72	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	72	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	74	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		none	11170	none	11170
Norverapamil	Verapamil	73	74	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		none	11170	none	11170
Norverapamil	Verapamil	73	75	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		none	11170	none	11170
Norverapamil	Verapamil	73	75	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		none	11170	none	11170
Norverapamil	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	11170	none	11170
Norverapamil	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	11170	none	11170
Norverapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	none	none	C016904
Norverapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	none	none	C016904
Norverapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	none	none	C016904
Norverapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	none	none	C016904
Norverapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	none	none	C016904
Norverapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	none	none	C016904
Norverapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	none	none	C016904
Norverapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	none	none	C016904
Norverapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	none	none	C016904
Norverapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		none	none	none	C016904
Norverapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	none	none	C016904
Norverapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	none	none	C016904
Norverapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	none	none	C016904
Norverapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	none	none	C016904
Norverapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	none	none	none
relaxant	Verapamil	30	29	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
relaxant	Verapamil	30	29	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
relaxant	Verapamil	30	31	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		none	11170	none	11170
relaxant	Verapamil	30	31	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		none	11170	none	11170
relaxant	Verapamil	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
relaxant	Verapamil	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
verapamil hydrochloride	Verapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	48	false	none	Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	48	false	none	Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	55	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	55	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ngh/ml and 195 ngh/ml for the S isomer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	34	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	34	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	36	false	none	The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	36	false	none	The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	41	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	41	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	55	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	55	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	59	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	59	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	58	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	58	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	45	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	45	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	48	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	48	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	47	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	47	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	none	D014700	C016904
Verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
Verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
Verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
Verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
Verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
Verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
Verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
Verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
Verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
Verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
Verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
Verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
Verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
Verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
Verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
norverapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	none	C016904	none
